Adaptive Biotechnologies Says Its Next-generation Sequencing-based clonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting

5/31/24 7:35:14 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ADPT alert in real time by email

The meeting will be taking place from May 31-June 4 in Chicago. Company will also present at the European Hematology Association (EHA) Hybrid Congress taking place June 13-16 in Madrid and virtually.

Get the next $ADPT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ADPT

Date	Price Target	Rating	Analyst
7/5/2023	$15.00	Overweight	JP Morgan
1/5/2023	$15.00	Sector Outperform	Scotiabank
12/21/2022	$7.50 → $14.00	Neutral → Overweight	Piper Sandler
8/25/2022	$8.00	Underperform	Credit Suisse
6/3/2022	$7.50	Neutral	Piper Sandler
2/16/2022	$40.00 → $32.00	Buy	BofA Securities
2/16/2022	$75.00 → $50.00	Overweight	JP Morgan
2/16/2022	$54.00 → $21.00	Neutral	Goldman

More analyst ratings

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2024. "Our focus on execution and disciplined capital allocation are driving MRD growth with a clear path to profitability while we continue to advance our targeted Immune Medicine programs," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "The increased clonoSEQ® Medicare Gapfill rate and the extensio
11/7/24 4:05:00 PM ET
$ADPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established based on updated clonoSEQ gapfill rate SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its Molecular Diagnostics Services Program (MolDX), has expanded coverage of clonoSEQ® to include detection and monitoring of
11/7/24 7:30:55 AM ET
$ADPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2024 after market close on Thursday, November 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 ho
10/9/24 4:05:00 PM ET
$ADPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor
On Monday, Cathie Wood-led Ark Invest made a notable investment in Palantir Technologies Inc (NYSE:PLTR), a move that comes as the AI sector gains momentum. The PLTR Trade Ark Invest, through its ARK Autonomous Technology & Robotics ETF (BATS:ARKQ), purchased 199,372 shares of Palantir, a significant addition to its portfolio. The value of this trade, based on the closing price of $25.88 on the same day, stands at approximately $5.16 million. Palantir has recently been praised as an ‘AI Halo’ play by momentum investors. The company was added to BofA Securities’ top 10 best U.S. ideas list for the third quarter, highlighting its growing popularity in the AI sector. Joe Terranova of V
7/1/24 10:19:40 PM ET
$ADPT
$BLDE
$PLTR
$RXRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Transportation Services
Consumer Discretionary
Adaptive Biotechnologies Says Its Next-generation Sequencing-based clonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting
The meeting will be taking place from May 31-June 4 in Chicago. Company will also present at the European Hematology Association (EHA) Hybrid Congress taking place June 13-16 in Madrid and virtually.
5/31/24 7:35:14 AM ET
$ADPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Adaptive Biotechnologies Q1 2024 GAAP EPS $(0.33) Beats $(0.35) Estimate, Sales $41.873M Beat $38.784M Estimate
Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.35) by 5.71 percent. This is a 17.5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $41.873 million which beat the analyst consensus estimate of $38.784 million by 7.96 percent. This is a 11.23 percent increase over sales of $37.647 million the same period last year.
5/7/24 4:37:44 PM ET
$ADPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$ADPT
Financials

Live finance-specific insights

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2024. "Our focus on execution and disciplined capital allocation are driving MRD growth with a clear path to profitability while we continue to advance our targeted Immune Medicine programs," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "The increased clonoSEQ® Medicare Gapfill rate and the extensio
11/7/24 4:05:00 PM ET
$ADPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2024 after market close on Thursday, November 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 ho
10/9/24 4:05:00 PM ET
$ADPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2024. "We had another strong quarter with MRD revenue growth of 36% and delivered significant reductions in operating spend and cash burn versus prior year," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "I am encouraged by our progress towards MRD profitability and our execution on key Immune Medicine prog
8/1/24 4:05:00 PM ET
$ADPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Adaptive Biotechnologies Says Its Next-generation Sequencing-based clonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting

Chat with this insight

Recent Analyst Ratings for $ADPT

$ADPT FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

$ADPT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Commercial Officer, MRD Bobulsky Susan exercised 5,000 shares at a strike of $1.98, increasing direct ownership by 2% to 253,290 units (SEC Form 4)

SVP and General Counsel Taylor Stacy L sold $121,079 worth of shares (26,922 units at $4.50), decreasing direct ownership by 16% to 139,365 units (SEC Form 4)

Piskel Kyle was granted 31,260 shares, increasing direct ownership by 25% to 154,578 units (SEC Form 4)

$ADPT Leadership Updates

Live Leadership Updates

Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas

Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer

$ADPT SEC Filings

SEC Form 10-Q filed by Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Adaptive Biotechnologies Corporation

$ADPT Press Releases

Fastest customizable press release news feed in the world

$ADPT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$ADPT Market Insights

Live Market Insights

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

JP Morgan resumed coverage on Adaptive Biotechnologies with a new price target

Scotiabank initiated coverage on Adaptive Biotechnologies with a new price target

Adaptive Biotechnologies upgraded by Piper Sandler with a new price target

Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor

Adaptive Biotechnologies Says Its Next-generation Sequencing-based clonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting

Adaptive Biotechnologies Q1 2024 GAAP EPS $(0.33) Beats $(0.35) Estimate, Sales $41.873M Beat $38.784M Estimate

$ADPT Financials

Live finance-specific insights

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

$ADPT Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Adaptive Biotechnologies Corporation

SEC Form SC 13G filed by Adaptive Biotechnologies Corporation

Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

Recent Analyst Ratings for
$ADPT

$ADPT
FDA approvals

$ADPT
Insider Trading

$ADPT
Leadership Updates

$ADPT
SEC Filings

$ADPT
Press Releases

$ADPT
Analyst Ratings

$ADPT
Market Insights

$ADPT
Financials

$ADPT
Large Ownership Changes